Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
BioAtla & GATC Health: Oz-V Phase III Oncology Trial
BioAtla and GATC Health partner to advance Ozuriftamab vedotin (Oz-V) into Phase III trials for OPSCC. Explore the $40M SPV transaction and AI-driven drug discovery.
GLP-1 Agonists: Neuroprotection & Dementia Prevention Study
New Karolinska Institutet research shows GLP-1 agonists reduce dementia risk by 30%. Discover neuro-metabolic drug discovery targets at ChemDiv.
36
37
38
39
40
